The (un)foreseen consequences of molecular classification in pathology: lessons from central nervous system tumors.
文献摘要
Objectives To examine the downstream consequences of incorporating molecular markers into disease classification, using the World Health Organization classification of central nervous system (CNS) tumors as a case study for broader developments in pathology. Methods We conducted a narrative review of the historical development and implementation of molecular CNS tumor classification and analyzed its consequences across diagnostic practice, epidemiology, clinical research, precision medicine, global health, patient experience, ethics, and diagnostic commercialization. Results Molecularly defined categories have improved diagnostic precision and accuracy by aligning diagnoses more closely with tumor biology, prognosis, and therapeutic response. However, they have also shifted diagnostic uncertainty toward assay performance, technical infrastructure, and specialized molecular-pathologic expertise. Histomolecular reclassification complicates tumor registration, epidemiologic comparisons, and the interpretation of premolecular clinical studies because historical histologic entities do not necessarily correspond to contemporary tumor types. Molecular classification further affects trial design and targeted therapy development while raising questions regarding feasibility, regulation, access, and equity. These challenges are particularly relevant in low- and middle-income countries with limited testing capacity, specialist expertise, and quality assurance systems. Molecular categories may also influence patient identity and self-advocacy, create ethical responsibilities related to unsolicited findings, and strengthen the relationship between classification systems and commercial diagnostic technologies. Conclusions Molecular classification should not be understood as merely a technical refinement of diagnosis. Its effects extend across the clinical, scientific, epidemiologic, administrative, ethical, and commercial infrastructures of pathology.